Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 13/20 | 0.60 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.51 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 2/20 | 0.46 |
| ▸ | PYGL | P06737 | 2/20 | 0.41 |
| ▸ | PYGM | P11217 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191956 | 1.00 | RIPK1 (0.60) | RIPK1SCN9ABRPF1XIAPPYGL | |
| SCHEMBL4429111 | 0.83 | SCN9A (0.65) | RIPK1SCN9ABRPF1XIAPPYGL | |
| SCHEMBL4423218 | 0.83 | SCN9A (0.65) | RIPK1SCN9ABRPF1XIAPPYGL | |
| SCHEMBL9989170 | 0.81 | RIPK1 (0.52) | RIPK1SCN9ABRPF1XIAPPYGL | |
| SCHEMBL9990232 | 0.80 | RIPK1 (0.52) | RIPK1SCN9ABRPF1XIAPPYGL | |
| SCHEMBL9989198 | 0.78 | RIPK1 (0.48) | RIPK1SCN9ABRPF1XIAPPYGL | |
| SCHEMBL15956793 | 0.76 | RIPK1 (0.57) | RIPK1SCN9AXIAPPYGLPYGM | |
| SCHEMBL21307399 | 0.76 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL17312763 | 0.76 | RIPK1 (0.71) | RIPK1 | |
| SCHEMBL17312646 | 0.76 | RIPK1 (1.00) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075971-A1 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-03-19 | — | — | US | disclosed |
| EP-2029555-A2 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | Sanofi-Aventis (FR) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007135295-A2 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075971-A1 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | CYP4B1, AADAC, ALKBH3 | RIPK1 4874/4885SCN9A 3603/4885BRPF1 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.